Please select the eligibility criteria that correspond to the clinical trial below.
Title: PPAR Alpha (LY518674): A Phase 2 Study of the Combinatorial Effect of LY518674 and Atorvastatin in Subjects With Hypercholesterolemia
Brief Summary: The purposes of this study are to determine:

* The safety of the study medication and any side effects that might be associated with it
* Whether the study medication can help patients with high levels of "bad" cholesterol (low-density lipoprotein-cholesterol \[LDL-C\]), alone or in combination with additional study medication


Options:
A: Inclusion Criteria:

* Male or female 18 to 65 years of age.
* Weight\> 50 kg and \<95 kg inclusive
* For women of childbearing potential, a negative serum pregnancy test at the screening visit and a negative urine pregnancy test on day 1.
* For men and women of childbearing potential, willingness to utilize adequate contraception and not become pregnant (or have their partner\[s\] become pregnant during the full duration of the study.
* Willing, committed, and able to return for all clinic visits and complete all study-related procedures.
* Able to read, understand and willing to sign the informed consent form.

Exclusion Criteria:

* Initiation of a new exercise routine or major change to a previous exercise routine within 4 weeks prior to screening visit.
* Pregnant or breast-feeding females.
* Significant concomitant illness or history of significant illness such as cardiac, renal, neurological, endocrinological, metabolic or lymphatic disease, or any other illness or condition that would adversely affect the subject's participation in this study.
* Hospitalization for any reason within 60 days of screening.
* Known history of Human Immunodeficiency Virus (HIV) antibody; and/or positive Hepatitis B surface antigen, and/or positive Hepatitis C antibody at the screening visit.
* Previous exposure to any therapeutic or investigational biological agent.
* History of alcohol or substance abuse within previous 5 years.
B: Inclusion Criteria:

* Men and women between 18 and 80 years of age
* People with abnormal cholesterol levels

Exclusion Criteria:

* People with diabetes
* People whose blood pressure \>160/95 mm Hg, on or off blood pressure medicine
* People who have had frequent chest pain or unstable angina, a heart attack or a heart procedure including stent placement, within the past 3 months
C: Inclusion Criteria:

* Diabetes mellitus treated with insulin or orl agents
* At least 50 years old

Exclusion Criteria:

* Previous cardiovascular events
* current or past (within last 30 days) treatment with aspirin
* current or past (within last 180 days) treatment with statins
D: Inclusion Criteria:

* Age≥18 years old
* LVEF ≤ 35%, as documented by echocardiography, radionuclide ventriculography, gated SPECT, or contrast ventriculography within past 6 months
* Symptomatic HF (NYHA II-IV) or current NYHA I with history of symptomatic HF within the last year
* Stable doses of optimal HF medical therapy, unless documented contraindication.

Exclusion Criteria:

* Ischemic etiology of HF, defined as the presence of at least one of the following four criteria; angiographic evidence of \> 50% lesion in 1 or more of the 3 major epicardial vessels; history of myocardial infarction; history of revascularization procedure; evidence of significant perfusion defect in the setting of ischemic symptoms.
* Clinical indication for statin treatment - coronary artery, cerebrovascular, or peripheral vascular disease
* Major cardiovascular event or surgical procedure within past 8 weeks
* LDL\<70 mg/dL
* HF secondary to congenital heart disease or uncorrected valvular disease
* Treatment with statin within past 2 months
* Pregnancy
* Contraindication to statin: moderate liver disease, AST/ALT \> 150 U/ L, known hypersensitivity
* Likely to receive heart transplant within 3 months
* Known peripheral or autonomic neuropathy

Answer: B